Acute myeloid leukemia with 11q23 abnormalities
MONDO:0020317An acute myeloid leukemia associated with t(9;11)(p22.3;q23.3) and MLLT3-KMT2A fusion protein expression. Morphologically it usually has monocytic features. It may present at any age but it is more commonly seen in children. Patients may present with disseminated intravascular coagulation.
Also known as: AML with 11q23 abnormalities, AML with t(9;11)(p22;q23); MLLT3-MLL, acute myeloid Leukaemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A, acute myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A, acute myeloid leukaemia with 11q23 (MLL) abnormalities, acute myeloid leukaemia with MLL abnormalities, acute myeloid leukaemia with t(9;11)(p22.3;q23.3); MLLT3-KMT2A, acute myeloid leukaemia with t(9;11)(p22;q23); MLLT3-MLL
3098 clinical trials for this condition and its sub-types, 11 tagged with Acute myeloid leukemia with 11q23 abnormalities itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
Can a Platelet-Boosting drug speed recovery for older leukemia patients?
Disease control CompletedThis phase II trial investigates whether eltrombopag, a drug that stimulates platelet production, can help older adults with acute myeloid leukemia (AML) recover their platelet counts faster after initial chemotherapy. Older patients often experience slow platelet recovery, which…
Phase 2 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Could a targeted drug keep AML in check?
Disease control CompletedThis phase III trial tests whether the drug tipifarnib can prevent acute myeloid leukemia (AML) from coming back in patients who are already in remission. Participants include adults over 60 in first remission, those in second or later remission, or those who achieved remission a…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Could a Gene-Targeting drug boost chemo for older leukemia patients?
Disease control CompletedThis study tested whether adding a drug called oblimersen to standard chemotherapy (daunorubicin and cytarabine) helps older adults (60+) with untreated acute myeloid leukemia live longer or achieve remission. About 500 participants were randomly assigned to receive chemo with or…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New Two-Step transplant shows promise for blood cancer patients
Disease control CompletedThis study tested a two-step stem cell transplant for people with blood cancers like leukemia and lymphoma. First, patients received low-dose chemotherapy and radiation to prepare their bodies. Then, they got donor stem cells followed by drugs to prevent the donor cells from atta…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Drug duo shows promise for Tough-to-Treat leukemia
Disease control CompletedThis phase II trial tested two drugs—sirolimus and azacitidine—in 57 people with high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that had come back or didn't respond to standard treatment. The goal was to see if the combination could shrink or control the…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Experimental drug pair targets tough leukemias
Disease control CompletedThis early-phase trial tested a combination of two drugs—veliparib and temozolomide—in 66 adults with relapsed or refractory acute leukemias. Veliparib blocks a DNA repair enzyme, while temozolomide damages cancer cell DNA. The goal was to find the safest dose and check for side …
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC